US-based medical device firm SentreHeart has completed patient enrolment in stage I of its aMAZE trial for LARIAT Suture Delivery System (LARIAT).

The aMAZE trial evaluates the outcomes of LARIAT in closure of left atrial appendage in combination with pulmonary vein isolation catheter ablation, in patients with drug-refractory, persistent and long-standing persistent AFib.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Stage I of the trial examines the safety and performance of the LARIAT procedure in the first 100 consecutively enrolled subjects.

"The rapid completion of this significant enrolment milestone demonstrates that clinicians and patients are seeking new therapeutic options for the treatment of persistent and long-standing persistent AFib."

With the first subject enrolled in October 2015, the firm is currently enlisting subjects at 34 US centres, with plans to expand to 50 centres.

SentreHeart chief executive officer and president Russ Seiber said: “We are delighted by the enrolment progress of the aMAZE Trial and are excited have achieved our 2016 enrollment objectives.

See Also:

“The rapid completion of this significant enrolment milestone demonstrates that clinicians and patients are seeking new therapeutic options for the treatment of persistent and long-standing persistent AFib.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AFib is an irregular, rapid heartbeat of the heart's atria caused due to a malfunction in the organ's electrical system.

The studies conducted indicate that LARIAT closes the LAA mechanically as well as isolates electrical activity within the LAA, which can be used to treat patients with persistent or longstanding persistent AFib.

The LARIAT can remove LAA as a source of AFib and nidus for thrombus.

In the trial, the percutaneous, non-implant LARIAT suture delivery device is used to treat AF by mechanically and electrically isolating the base of the LAA

SentreHeart intends to enroll a total of approximately 600 patients for the aMAZA trial.